Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial.

Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial.

<h4>Background</h4>Current tuberculosis treatments leave most patients with bronchiectasis and fibrosis, permanent conditions that impair lung function and increase all-cause post-TB mortality. Host-directed therapies (HDTs) may reduce lung inflammation and hasten eradication of infectio...

Full description

Bibliographic Details
Main Authors: Robert S Wallis, Sibuse Ginindza, Trevor Beattie, Nishanee Arjun, Morongwe Likoti, Modulakgotla Sebe, Vinodh A Edward, Mohammed Rassool, Khatija Ahmed, Katherine Fielding, Bintou A Ahidjo, Mboyo D T Vangu, Gavin Churchyard
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0252097&type=printable

Internet

https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0252097&type=printable

Similar Items